Compare USNA & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USNA | ASMB |
|---|---|---|
| Founded | 1992 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.1M | 442.9M |
| IPO Year | 1996 | 2010 |
| Metric | USNA | ASMB |
|---|---|---|
| Price | $22.71 | $25.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $44.20 |
| AVG Volume (30 Days) | 97.6K | ★ 245.6K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $1,060,902,000.00 | N/A |
| Revenue This Year | $3.90 | N/A |
| Revenue Next Year | $6.21 | $638.39 |
| P/E Ratio | $54.70 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.60 | $16.90 |
| 52 Week High | $38.32 | $39.71 |
| Indicator | USNA | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 65.03 | 44.98 |
| Support Level | $18.71 | $21.80 |
| Resistance Level | $22.64 | $30.47 |
| Average True Range (ATR) | 1.01 | 1.42 |
| MACD | 0.06 | -0.10 |
| Stochastic Oscillator | 85.97 | 27.00 |
Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.